Current WHO model for
development / preservation of new
antibiotics

13 May 2014

Marie-Paule KIENY, ADG/HIS
Some assumptions

- Innovators should be rewarded, within reason
- No additional profit should be provided for higher volume sales
- Discovery and innovation takes place mostly in the academia and small companies rather than large companies
- LMICs, and in particular emerging countries, have enormous untapped innovation capacity
- PDPs have been able to drive the development of new drugs
- Some "generics" companies have high technical capacity
- Self-regulation by manufacturers and users unlikely, esp due to over-the-counter LMIC markets and "counterfeit" medicines
- (some) companies would work "on contract" provided the offer is sufficiently attractive
- Preservation will require GLOBAL arrangements
- New antibiotics should be a Global Public Good
- Access should be ensured without regard to ability to pay
Innovation

Development (under contract)

Production (under contract, cost +++)

Academics

Biotechs

Pharma

"IFPMA" or Generic manufacturers

Milestone Prizes

Grants

Initiative

Governments' Consortium

IP

WHO; Patent pool?

c.a. $US several Billion

Antibiotics X, Y, Z... belong to the consortium

Managed Market

- Supply controlled
- No sales in pharmacies
- Observed treatment compliance
- Access of DC at cost+ (for sustainability)
- No licenses provided to third parties

= no risk for Pharma

PDP-like management of operations

= =

- Supply controlled
- No sales in pharmacies
- Observed treatment compliance
- Access of DC at cost+ (for sustainability)
- No licenses provided to third parties

= =
## SWOT analysis

### Strengths
- Delinkage model
- Ensures both incentivization of R&D AND preservation
- Access and affordability for ALL countries
- Transparency
- Strong global governance
- Operations overseen by competent agent
- Clinical trials financed by consortium
- Incentives on Products and/or Pathogens possible

### Weaknesses
- May need UN-level agreement
- Need for global IP management arrangements to ensure Exclusivity in perpetuity and compulsory licenses

### Opportunities
- Leverage science in LMIC in addition to HIC
- Engage LMIC manufacturers
- Exploration of natural compounds in LMIC
- Will use both Push and Pull financial mechanisms: prizes, grants, pooled fund
- Multinational companies willing to support delinkage models
- Potential for simultaneous worldwide registration
- Sharing of safety information and global arrangements on safety claims
- Development of POC Dx in conjunction with Abx

### Threats
- Lack of political leadership (shared responsibility)
- Insufficient financial investment
- "Classification" could make access in LIC challenging (as for opioids)
- Push-back from animal sector